Participants 113 171 3
operable breast cancer with 0 to 3 positive axillary nodes
Participants 545 568 4
operable breast cancer.
Participants 590 737 8
Women with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was greater than 1 cm
Participants 739 1053 5
Patients were randomly assigned after surgery to receive doxorubicin (60 mg/m(2)) plus either cyclophosphamide (600 mg/m(2); AC) or docetaxel (60 mg/m(2); AT) given every 3 weeks for four cycles, followed by hormone therapy for patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors
Participants 1074 1107 6
2,882 eligible patients enrolled.
